IGFBP2 and myeloid sarcoma: The serum levels of IGFBP-2 between MS patients and the control group were investigated by Torres-Aleman et al., Hosback et al., and Wilczak et al. [15, 16, 18] studies, in which they failed to demonstrate any significant difference between the groups.